Medivisor has signed an agreement with Cura Pharmaceutical to market the product Albumax, a whey protein isolate formula that enables kidney disorder patients to reach their daily requirements of high quality protein in their diet.
Under the terms of the Agreement, Cura will continue to be responsible for manufacturing, regulatory, medical, clinical development, pricing and distribution for the product while Medivisor is responsible for sales and marketing.
According to the company, a small pilot study of Albumax showed that patients’ serum albumin levels consistently increased while taking Albumax and dropped when they discontinued use of Albumax. Of the patients that discontinued Albumax and then restarted, their serum albumin decreased when Albumax was discontinued and showed increases upon restarting Albumax.
Dino Luzzi, CEO of Medivisor, said: “We are extremely pleased that Cura has chosen Medivisor as their partner in developing the market for this product in the US. With the announcement of this agreement we also launched www.albumax.net which has given the product a web presence.
“Over the next few weeks our next initiatives will be to work with the individual state reimbursement divisions of Medicaid to define Albumax as a special nutritional composition which is essential for the dietary management of the disease process.”